ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
Dow Jones
44.424,25
-0,32%
Euro vs US Dollar
1,05025
0,00%
Bitcoin
104.543,80
-0,18%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) News

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NBIX
DatumZeitQuelleÜberschriftSymbolFirma
23/01/202522h05PR Newswire (US)Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and DeviceNASDAQ:NBIXNeurocrine Biosciences Inc
21/01/202522h05PR Newswire (US)Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
17/01/202522h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
15/01/202522h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/01/202514h30PR Newswire (US)Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
06/01/202522h01PR Newswire (US)Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
03/01/202522h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
31/12/202422h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202414h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202414h00PR Newswire (US)Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
19/12/202422h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
19/12/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
17/12/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
14/12/202400h55PR Newswire (US)Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
04/12/202400h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
29/11/202419h41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
26/11/202422h01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in DecemberNASDAQ:NBIXNeurocrine Biosciences Inc
12/11/202423h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/11/202401h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
07/11/202414h30PR Newswire (US)Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
05/11/202422h01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in NovemberNASDAQ:NBIXNeurocrine Biosciences Inc
04/11/202414h30PR Newswire (US)Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
04/11/202414h25PR Newswire (US)Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive DyskinesiaNASDAQ:NBIXNeurocrine Biosciences Inc
02/11/202400h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/11/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202412h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202412h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202412h00PR Newswire (US)Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
11/10/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
09/10/202422h01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX

Kürzlich von Ihnen besucht

USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
DBI
SDXP
SDAX
COIN
DOGEUSD
Dogecoin
COIN
XRPUSD
Ripple
NASDAQ
NVDA
NVIDIA
TG
MBG
MercedesBenz
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BNPQY
BNP Paribas (QX)
TG
D7G
Nel ASA
TG
RHM
Rheinmetall
COIN
BTCUSD
Bitcoin
FX
EURGBP
Euro vs Sterling
AMEX
XLV
Health Care Select Sector
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten